Drug Profile
Research programme: single-stranded RNAi therapeutics - Alnylam/Isis
Alternative Names: ssRNAi research programme - Alnylam/IsisLatest Information Update: 22 Mar 2011
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Isis Pharmaceuticals
- Class Oligonucleotides; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Apr 2009 Early research in Undefined indication in USA (unspecified route)